Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study

BACKGROUND: Patients with diabetes have a two to fourfold increased risk for development of and death from cardiovascular disease [CVD]. The current oral hypoglycaemic agents result in limited reduction in this cardiovascular risk. Sodium glucose linked co-transporter type 2 [SGLT2] inhibitors are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Alexander J.M., Lang, Chim, McCrimmon, Rory, Struthers, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569551/
https://www.ncbi.nlm.nih.gov/pubmed/28835229
http://dx.doi.org/10.1186/s12872-017-0663-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569551/
https://www.ncbi.nlm.nih.gov/pubmed/28835229
http://dx.doi.org/10.1186/s12872-017-0663-6

Ejemplares similares